The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Exclusion Criteria

• •Zollinger-Ellison syndrome or other gastric hypersecretory condition
• •Acute peptic ulcer and/or ulcer complications
• •Pyloric stenosis
• •Severe or unstable cardiovascular, pulmonary, and/or endocrine disease
• •Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of child-bearing potential
• •Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start
• •Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day